MicroRNA-126(miR-126)对血管调节的分子机制

脉管系统的结构,维护及重塑的精确调节对于血管的正常发育,组织损伤的应答和肿瘤的生长都是必不可少的。最近,越来越多的研究报道了非编码的RNAs,又叫做microRNAs调节内皮细胞对血管原刺激的应答反应。在体内,维持血管内皮细胞和血管的完整性方面miR-126是一种重要的血管生成信号调节因子。miR-126通过负性调控血管生长因子促进血管发生反应,这些血管因子包括血管内皮生长因子(VEGF)和碱性成纤维细胞生长因子(bFGF)。因此,miR-126表达的靶向作用也许对于血管过多或缺乏引起的相关疾病开辟了一种新的治疗方法,这些发现也证实了单一miRNA能够调节血管的完整性及血管生成,为调整血管的形态和功能提供了一个新的靶点。本文就当前miR-126对血管的调节及分子机制进行综述。     

miR-126报告基因载体的构建及其功能鉴定

目的:根据miR-126的预测靶点构建荧光素酶报告基因重组质粒,并进行功能鉴定。方法:利用sanger数据库提供的miR-126靶序列设计引物,PCR扩增目的微小RNA(microRNAs,miRNAs)靶基因3'非编码区(three-prime untranslated regions,3'UTRs)序列,PCR产物双酶切,后连入经过同样双酶切的pGL3-control载体中,连接产物转化大肠杆菌DH5α,进行阳性克隆鉴定。同样,将候选靶基因3'UTRs突变,突变型3'UTR克隆入pGL3-control报告载体,构建野生型和突变型的报告基因重组质粒。将野生型和突变型的报告基因载体分别和化学合成的microRNA以及内参质粒共转染293TN细胞,进行双荧光素酶检测。结果:成功构建miR-126报告基因野生型和突变型重组质粒pGL3-VEGF-A-3'UTR和pGL3-VEGF-A-3'UTR,质粒测序及酶切结果完全正确。瞬时转染实验显示,过表达miR-126能直接抑制VEGF-A-3'UTRs报告基因活性。结论:miR-126对VEGF-A具有靶向调节功能。     

miR-126 调控前列腺癌机制研究

miR-126通过靶向作用于表皮生长因子域7(EGFL7)、同源框A9(HOXA9)、胰岛素受体底物-1(IlLS-1)、p85-B基因等,在转录后水平调控靶基因表达,在肿瘤形成中起重要作用。前列腺癌细胞中高表达miR-126,能明显下调VEGF-A、EGLF7、HOXA9、VCAM-l等与肿瘤生长、转移密切相关的蛋白分子。miR-126作为抑癌因子,在多种肿瘤中均下调。其抑癌作用及机制在肺癌、白血病、乳腺癌、宫颈癌等中均已得到证实。本课题拟对miR-126调控前列腺癌机制做一综述。     

miR-126调控前列腺癌机制研究

miR-126通过靶向作用于表皮生长因子域7（EGFL7）、同源框A9（HOXA9）、胰岛素受体底物-1（11LS-1）、p85-B基因等,在转录后水平调控靶基因表达,在肿瘤形成中起重要作用。前列腺癌细胞中高表达miR,126,能明显下调VEGF—A、EGLF7、HOXA9、VCAM—1等与肿瘤生长、转移密切相关的蛋白分子。miR-126作为抑癌因子,在多种肿瘤中均下调。其抑癌作用及机制在肺癌、白血病、乳腺癌、宫颈癌等中均已得到证实。本课题拟对miR-126调控前列腺癌机制做一综述。     

miR126功能的多效性与先天性免疫

MicroRNAs (miRNAs)是一种重要的转录后水平进行调控的非编码小分子RNA。目前已发现许多miRNAs参与细胞增殖、分化、发育及凋亡等复杂的生物进程, 其中miR126是一种来源于Egfl7第7个内含子的保守型内含子miRNA, 主要在哺乳动物的内皮细胞(Endothelial cells, ECs)及浆细胞样树突状细胞(Plasmacytoid dendritic cells, pDCs)内表达, 参与血管的新生及癌细胞的增殖与迁移。最新的研究表明, miR126是迄今唯一参与先天性免疫平稳期病毒应答反应的miRNA, 预示着miR126有可能成为治疗癌症及免疫缺陷病的靶标分子。文章综述了miR126在血管新生和癌症中的功能, 并着重介绍了miR126与先天性免疫的关系。     

miR-126、miR-31在运动神经元与神经干细胞分化所得胆碱能神经元间表达情况的比较

目的了解运动神经元和神经干细胞诱导分化所得胆碱能神经元间miR-126和miR-31的差异表达情况,并以此来探讨两种细胞之间的差异。方法应用ABI公司的TaqMan MicroRNA Assays real-time PCR技术,观察miR-126和miR-31在运动神经元与神经干细胞分化所得胆碱能神经元中的表达情况。结果 miR-126在神经干细胞分化所得胆碱能神经元中的表达是在运动神经元中的0.002倍(P<0.05)。miR-31在神经干细胞分化所得胆碱能神经元中的表达是在运动神经元中的56.444倍(P<0.05)。结论 miR-126和miR-31在运动神经元与神经干细胞分化所得胆碱能神经元中的表达存在差异,对二者预测靶基因参与的生物学过程分析,暗示两种细胞可能在信号传导和发育上存在有差别。     

截短型rhtBIGH3-(RGD)2蛋白通过上调miR-126 表达抑制 人脐静脉内皮细胞的生物活性

目的:探讨miR-126在截短型rhtBIGH3-(RGD)_2蛋白抑制HUVEC细胞生物学活性中的作用。方法:体外培养VEGF孵化的人脐静脉内皮细胞(VEGF-HUVEC),分别加入rhtBIGH3-(RGD)_2蛋白终浓度为0和100μg/mL,作用24、48、72 h条件下,分别检测Caspase-3活性和miR-126表达水平。在rhtBIGH3-(RGD)_2蛋白终浓度为0和100μg/mL时,分别加入miR-126 mimic和miR-126 inhibitor,作用VEGF-HUVEC 48 h后,Real-time PCR检测miR-126表达水平,通过检测Caspase-3活性来检测细胞凋亡情况。结果:在VEGF-HUVEC中,当rhtBIGH3-(RGD)_2蛋白终浓度为100μg/mL条件下,Caspase-3水平升高,miR-126表达水平升高,在48 h下达到最高峰。在VEGF-HUVEC中,当rhtBIGH3-(RGD)_2蛋白终浓度分别为100μg/mL条件下,加入miR-126mimic后,miR-126表达升高,Caspase-3水平升高;加入miR-126 inhibitor后,48 h后检测miR-126表达下降,Caspase-3水平也下降。结论:截短型rhtBIGH3-(RGD)_2蛋白通过上调miR-126表达从而促进细胞凋亡、抑制HUVEC生物活性,从而抑制角膜新生血管的发生     

miR-126 在膀胱癌患者尿液中的表达及临床意义

目的:探讨miR-126在膀胱癌患者尿液中的表达与临床病理特征的关系,评估miR-126的肿瘤标志物诊断价值。方法:收集48例初发膀胱尿路上皮癌患者与32例健康对照者晨尿,提取尿液总RNA,通过实时荧光定量PCR技术检测各样本中的miR-126的表达水平,并经受试者工作曲线(ROC)分析其诊断价值。结果:膀胱癌患者尿液中的miR-126表达水平相对健康对照组明显上调(P0.01),其表达水平在不同病理级别之间存在显著差异(P均0.05),且低级别组表达水平略高于高级别组,与肿瘤大小、数目以及淋巴转移也有一定的相关性(P0.05),而与患者的年龄、性别、TNM分期等均无相关性(P0.05)。通过ROC曲线分析尿液中miR-126诊断膀胱肿瘤的曲线下面积(AUC)为0.861,当最佳切点定在7.475时,miR-126诊断膀胱肿瘤的敏感性和特异性分别为75.0%、81.2%。结论:膀胱癌患者尿液中miR-126的表达差异能够反映病情进展程度,其表达水平对膀胱肿瘤的早期诊断及病情评估具有一定的价值。     

大鼠miR-126慢病毒表达载体的构建及其在肝星状细胞中的表达

目的：肝星状细胞（hepaticstellatecell,HSC）激活并发生表型改变是肝纤维化形成的关键,本实验期待通过构建慢病毒mo—miR．126,并体外转染Hsc,为研究miR．126在肝纤维化中的作用奠定实验基础。方法：PCR扩增miR-126的前体,构建miR．126的重组表达载体pCDH．CMV-MCS．EFl．copGFP-miR．126,脂质体法转染包装细胞293TN细胞,包装产生慢病毒,以293TN细胞绿色荧光蛋白（greenfluorescentprotein,GFP）的表达水平测定病毒滴度,构建重组慢病毒（Lentivims,LV）载体（Lv．miR．126）,体外转染活化的HSC．T6,荧光显微镜观察荧光阳性细胞百分率,real—timePCR检测miR一126转入水平。结果：经PCR扩增检测阳性菌落和测序证实,成功构建携带大鼠miR一126基因重组慢病毒载体。倒置荧光显微镜下观察可见包装细胞293TN呈绿色荧光,并测得滴度108〉ifu／ml。荧光显微镜下HSC的荧光阳性率在95％以上。Real—timePCR检测证实miR-126转染后获得了较高的表达。结论：成功构建大鼠慢病毒载体Lv—miR-126,并可在体外高效稳定表达,为本研究后续对miR-126靶点验证和功能研究奠定实验基础。     

miR-132的生物学功能

microRNA是生物内源性的非编码小RNA,选择性地作用于mRNA的3’非翻译区（UTR）,对基因的表达起重要的调控作用。miR-132是发现较早的microRNA之一,我们对其在癌症、感染、心血管疾病、神经系统调节等众多生命过程中的作用进行简要综述。     

Retracted: Curcumin ameliorates atherosclerosis through upregulation of miR-126

The potential usage of curcumin in diverse human diseases has been widely studied, including arteriosclerosis (AS). This study focused on investigating the relationship between curcumin and AS-associated microRNA, which may provide a better understanding of curcumin in a different mechanism. Human microvascular endothelial HMEC-1 cells were treated by curcumin alone or oxidized low-density lipoprotein (ox-LDL) plus curcumin, after which the following parameters were analyzed: cell viability, migration, and the expression of AS-associated factors. The regulatory effects of curcumin on miR-126 and signaling pathways involved in AS were then studied. Further, an animal model of AS was stimulated by feeding rabbits with 1% cholesterol diet. The effects of curcumin on the animal model were explored. We found that curcumin treatment significantly reduced HMEC-1 cells viability, migration, and the protein levels of MMP-2, MMP-9, and vascular endothelial growth factor (VEGF) in the presence or absence of ox-LDL. Meanwhile, the expression of VEGFR1 and VEGFR2 was repressed by curcumin. miR-126 was upregulated by curcumin. The abovementioned effects of curcumin on HMEC-1 cells were all attenuated when miR-126 was silenced. And also, VEGF was a target gene of miR-126, and curcumin could inhibit the activation of PI3K/AKT JAK2/STAT5 signaling pathways via miR-126. The effects of curcumin and its regulation on miR-126 and VEGF were confirmed in the animal model of AS. To sum up, curcumin exerted potent anti-AS property possibly via upregulating miR-126 and thereby inhibiting PI3K/AKT and JAK2/STAT5 signaling pathways.     

miR-126-3p is essential for CXCL12-induced angiogenesis

Atherosclerosis, in the ultimate stage of cardiovascular diseases, causes an obstruction of vessels leading to ischemia and finally to necrosis. To restore vascularization and tissue regeneration, stimulation of angiogenesis is necessary. Chemokines and microRNAs (miR) were studied as pro-angiogenic agents. We analysed the miR-126/CXCL12 axis and compared impacts of both miR-126-3p and miR-126-5p strands effects in CXCL12-induced angiogenesis. Indeed, the two strands of miR-126 were previously shown to be active but were never compared together in the same experimental conditions regarding their differential functions in angiogenesis. In this study, we analysed the 2D-angiogenesis and the migration assays in HUVEC in vitro and in rat's aortic rings ex vivo, both transfected with premiR-126-3p/-5p or antimiR-126-3p/-5p strands and stimulated with CXCL12. First, we showed that CXCL12 had pro-angiogenic effects in vitro and ex vivo associated with overexpression of miR-126-3p in HUVEC and rat's aortas. Second, we showed that 2D-angiogenesis and migration induced by CXCL12 was abolished in vitro and ex vivo after miR-126-3p inhibition. Finally, we observed that SPRED-1 (one of miR-126-3p targets) was inhibited after CXCL12 treatment in HUVEC leading to improvement of CXCL12 pro-angiogenic potential in vitro. Our results proved for the first time: 1-the role of CXCL12 in modulation of miR-126 expression; 2-the involvement of miR-126 in CXCL12 pro-angiogenic effects; 3-the involvement of SPRED-1 in angiogenesis induced by miR-126/CXCL12 axis.     

hsa-miR-126的靶基因预测及其生物信息学分析

目的:采用生物信息学的方法预测hsa-miR-126的靶基因及相关功能,为后续研究提供理论基础。方法:采用PubMed搜索hsa-miR-126相关文章,总结目前研究进展,使用mi RBase获得hsa-miR-126的基本信息,并用NCBI BLAST分析其序列保守性,以Targetscan、mi Randa及PicTar预测结果的两两交集为预测靶基因,并结合mi RTarBase上已证实的靶基因作为基因集合做GO分析和Pathway分析。结果:搜索PubMed获得相关文献24篇,多数研究集中于hsa-miR-126与肿瘤的关系,hsa-miR-126在多种物种间具有高度保守性,其5个预测靶基因和46个已证实靶基因于白细胞迁移、对糖皮质激素反应、促进内皮细胞增殖、蛋白信号转导等有功能富集(P0.01),于多种肿瘤如肾细胞癌、前列腺癌、非小细胞肺癌、胰腺癌有信号通路富集(P0.01)。结论:hsa-miR-126可能参与多种肿瘤的发生发展过程。